Internal Server Error

About Venrock

Venrock is a venture capital firm founded in 1969. It is primarily based out of Palo Alto, United States. As of May 2026, Venrock is an active investor, having invested in 437 companies, with 14 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series D round of CellCentric Overall, Venrock portfolio has seen 16 unicorns, 75 IPOs and 190 acquisitions including key companies like CloudFlare, athenahealth and Apple. A lot of funds co-invest with Venrock, with names like RA Capital Management sharing a substantial percentage of its portfolio. Venrock has team of 64 people including 19 partners.
Key Metrics
Portfolio Count
Portfolio Locations
Rounds of Entry
Series A, Series B & 9 more
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months

Venrock's List of Top Investments

Venrock has a portfolio of 437 companies, including 16 unicorns. Their most notable investments are in Luma and Rarible.Their portfolio spans across United States, Canada, United Kingdom and 13 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 35 other sectors, across stages such as Series A, Series B  and 9 more. Here is the list of top investments by Venrock:
Provider of cloud services for security, performance, and application development. The company delivers networking, security, and performance services through its connectivity cloud platform. It offers solutions for application security, application performance, and network services. The company's platform supports businesses in modernizing networks, securing workspaces, and optimizing web experiences.

Key facts about CloudFlare

  • Founded Year: 2009
  • Location: San Francisco (United States)
  • Annual Revenue: $2.17B as on Dec 31, 2025
  • Stage: Public
  • Total Funding till date: $332M
  • Employee Count: 6,964 as on Mar 31, 2026
  • Investors: HTIF, Fidelity Investments and 17 Others
  • Latest Funding Round: Post IPO, Aug 2021, $*****
  • Highlight: Public
Cloud-based administrative tool for healthcare providers. The company has developed EHR, practice management, and population health solutions. The features include EHR, practice management, revenue cycle management (RCM), patient engagement, population health services, care coordination, clinical decision support, and more.

Key facts about athenahealth

Technology company and product innovator developing consumer electronics. The firm designs smartphones, personal computers, tablets, wearables, and related hardware alongside proprietary operating systems and productivity applications. It provides integrated ecosystems including cloud computing, digital media distribution, payment processing, and enterprise software solutions. Services encompass content streaming platforms, mobile app marketplaces, augmented reality frameworks, and professional creative software suites. Continuous platform evolution maintains seamless hardware-software integration across personal computing and professional segments.

Key facts about Apple

Subscription-based anime streaming platform. It allows users to stream content under various categories, including anime series, shows, manga, drama, music, electronic entertainment, and more in various languages on multiple devices.

Key facts about Crunchyroll

  • Founded Year: 2006
  • Location: San Francisco (United States)
  • Stage: Acquired
  • Total Funding till date: $55.5M
  • Employee Count: 297 as on Mar 31, 2026
  • Investors: Venrock and TV TOKYO
  • Latest Funding Round: Series B, Aug 26, 2015, $*****
  • Highlight: Acquired
Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.

Key facts about Gilead

  • Founded Year: 1987
  • Location: Foster City (United States)
  • Annual Revenue: $29.4B as on Dec 31, 2025
  • Stage: Acquired
  • Employee Count: 14,608 as on Mar 31, 2026
  • Investors: BB Biotech, Temasek and 17 Others
  • Latest Funding Round: Post IPO, Jan 27, 2025, $*****
  • Highlight: Acquired

Venrock's Investments by Stage

Venrock has made 114 investments in Series A stage with an average round size of $19.6M, 82 investments in Series B stage with an average round size of $38M and 44 investments in Series C stage with an average round size of $65.1M.
Here are Venrock's investments by stage:
Stage of entry
No. of Investments
Series A
114
Series B
82
Series C
44
Seed
38
Post IPO
28
Others
40
Breakdown of Venrock's investments by stage of entrySeries A (114)Series B (82)
Note: We have considered here, only first round of investments

Venrock's Investments by Sector

Venrock has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, Enterprise Infrastructure and Consumer. Notably, it has invested in 348 Tech companies, 328 Enterprise (B2B) companies, 155 Software companies and at least 67 companies focusing on Saas.
Here are Venrock's investments by sector:
Sector
No. of Investments
Life Sciences
128
Enterprise Applications
116
High Tech
43
Enterprise Infrastructure
42
Consumer
30
Others
262
Breakdown of Venrock's investments by sectorsLife Sciences (128)Enterprise Applic... (116)
Note: We have considered here, only first round of investments

Venrock's Investments by Geography

Venrock has made most investments in United States (314), followed by Canada where it has made 7 investments.
Here are Venrock's investments by geography:
Country
No. of Investments
United States
314
Canada
7
United Kingdom
6
China
5
Israel
4
Others
12
Breakdown of Venrock's investments by countriesUnited States (314)Canada (7)
Note: We have considered here, only first round of investments

Venrock's recent investments

Venrock has made 8 investments in 2026 so far. CellCentric and Gitar are the latest among them.
Here are the most recent investments by Venrock:
Date
Company
Location
Round Details
Round Amount
Co-Investors
May 06, 2026
United Kingdom
Series D
3118
-
Apr 15, 2026
United States
Series A
3281
Apr 14, 2026
Denmark
Series C
2244
  [+15]
Mar 16, 2026
United States
Post IPO
5883
Mar 02, 2026
United States
Series E
8055

Unicorns in Venrock's Portfolio

Venrock has 16 unicorns in its portfolio - Altruist, Salsify, Clara and others. The most recent unicorn in their portfolio is Altruist. It became a unicorn in 2024, 4 years after Venrock first invested in it.
Here is a list of unicorns in Venrock's portfolio:
Tracxn Score
Company
Short Description
Founded year
Sector
Location
Company Stage
First Investment/ Acquisition Details
70
Portfolio management software for financial advisors
2018
Culver City
Series F
hgmekqw
61
Product content management and syndication platform for businesses
2012
Boston
Series F
dtqpoel
67
An end-to-end corporate payment solution for companies
2014
Cuauhtemoc
Series B
rklcbqk
52
Developer of containerized launch system and small satellite launch vehicle
2017
El Segundo
Series B
qskoavc
60
Provider of AI and ML-based intelligence systems
2019
Washington
Series B
mlujzdy

IPOs and Publicly Listed companies in Venrock's Portfolio

75 of Venrock's portfolio companies have become public. Artiva got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2024 at marketcap of $211M and Alto Neuroscience got listed on the New York Stock Exchange (NYSE) at marketcap of $409M.
Here are Venrock's portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Jul 19, 2024
Feb 22, 2021
Series B
8484
Feb 02, 2024
Mar 16, 2026
Post IPO
8394
Sep 12, 2023
Apr 19, 2022
Series A
3717
Jul 14, 2023
Dec 07, 2022
Series B
1064
Feb 10, 2023
Feb 08, 2024
Post IPO
5815

Acquired companies in Venrock's Portfolio

190 companies from Venrock's portfolio have been acquired. The most recent acquisition was KalVista in Apr 2026 by Chiesi Pharmaceuticals for $*****.
Here are Venrock's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Apr 29, 2026
Jul 22, 2015
Post IPO
7754
Apr 20, 2026
Apr 28, 2022
Series A
9051
Apr 19, 2026
-
-
3193
Apr 07, 2026
Oct 15, 2025
Series C
1010
Mar 17, 2026
Oct 18, 2022
Seed
9405

Team profile of Venrock

Venrock has a team of 64 members including 19 Partners, 1 Venture Partner and 25 Principals located in United States. Venrock's team sits on the board of 8 companies.
Here is a list of top team members in Venrock:
Name
Designation
Location
Board Memberships
Contact Details
Partner
New York City
-
-
Partner
Palo Alto
Partner
Palo Alto
-
Partner
New York City
-
Partner
San Francisco
Partner
Palo Alto
-
Partner
New York City
-
Partner
New York City
-
-
Partner
Palo Alto
-
Partner
Palo Alto
-
Partner
New York City
-

Co-investors of Venrock

Over the past 50 years, 2083 investors have co-invested in Venrock's portfolio companies. This includes funds and angels.

  • Invested before VenrockRA Capital Management, Orbimed and 548 others have invested in rounds before Venrock. There are 10 companies where RA Capital Management has invested before Venrock and 9 companies where Orbimed has invested before Venrock.
  • Top Co-investors of Venrock656 investors entered a company along with Venrock. These include investors like RA Capital Management (21 companies).
  • Invested after VenrockA total of 877 investors have invested in Venrock's portfolio after their investments. Top Investors include Fidelity Investments (14 companies), SVB (13 companies) and GGV Capital (9 companies).

Recent News related to Venrock

View all news related to Venrock

FAQs about Venrock

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford